Skip to main content
Top
Published in: Clinical Rheumatology 3/2017

01-03-2017 | Original Article

Echocardiographic findings in asymptomatic systemic lupus erythematosus patients

Authors: Abdel GaffarA. Mohammed, Abdulaziz A. Alghamdi, Mohammad A. ALjahlan, Ibrahim A. AL-Homood

Published in: Clinical Rheumatology | Issue 3/2017

Login to get access

Abstract

The aim of this study is to use transthoracic echocardiographic (TTE) imaging methods to identify cardiac dysfunction in asymptomatic systemic lupus erythematosus (SLE) patients and to determine the association between echocardiographic findings and serology. This is a prospective cross-sectional study where 50 patients with confirmed diagnoses of SLE were recruited from rheumatology outpatient clinics. Clinical and serological evaluation to confirm the diagnosis of lupus was done in all patients. Fifty SLE patients, 46 (92%) females and 4 (8%) males, were recruited. Anti-double-stranded DNA (Anti-dsDNA), anticardiolipin, lupus anticoagulant, and anti-β2-glycoproteins were positive in 52.1, 32.6, 13.3, and 15.6%, respectively. Transthoracic echocardiogram revealed mitral regurgitation in 16 patients (32%), pericardial effusion in16 patients (32%), aortic regurgitation in five patients (10%), and tricuspid regurgitation in 10 patients (20%). Eleven patients had left ventricular hypertrophy (22%), and eight patients had ventricular systolic dysfunction (16%). Only four patients had ventricular diastolic dysfunction (8%). A significant association between mitral and tricuspid valve regurgitation and positive anti-dsDNA (p < 0.018, p < 0.006, respectively) was found. Positive anticardiolipin antibodies, lupus anticoagulant, and anti-β 2 glycoprotein antibodies were also associated with mitral valve regurgitation (p values 0.044, 0.006, and 0.023), respectively. Active disease assessed by Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) was found to be associated with increased risk of mitral valvular leaflet thickening (p value 0.028). Performing regular transthoracic echocardiogram in asymptomatic SLE patients is important for early detection and appropriate treatment of cardiac lesions. Clinically quiescent but serologically active disease and presence of antiphospholipid antibodies were associated with structural heart abnormalities.
Literature
1.
go back to reference Al-Arfaj AS, Al-Balla SR, Al-Dalaan AN, Al-Saleh SS, Bahabri SA, Mousa MM, Sekeit MA (2002) Prevalence of systemic lupus erythematosus in Central Saudi Arabia. Saudi medical journal 23(1):87–89PubMed Al-Arfaj AS, Al-Balla SR, Al-Dalaan AN, Al-Saleh SS, Bahabri SA, Mousa MM, Sekeit MA (2002) Prevalence of systemic lupus erythematosus in Central Saudi Arabia. Saudi medical journal 23(1):87–89PubMed
3.
go back to reference Zuily S, Regnault V, Selton-Suty C, Eschwege V, Bruntz JF, Bode-Dotto E, De Maistre E, Dotto P, Perret-Guillaume C, Lecompte T, Wahl D (2011) Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies. Circulation 124(2):215–224. doi:10.1161/CIRCULATIONAHA.111.028522 CrossRefPubMed Zuily S, Regnault V, Selton-Suty C, Eschwege V, Bruntz JF, Bode-Dotto E, De Maistre E, Dotto P, Perret-Guillaume C, Lecompte T, Wahl D (2011) Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies. Circulation 124(2):215–224. doi:10.​1161/​CIRCULATIONAHA.​111.​028522 CrossRefPubMed
4.
go back to reference Doria A, Iaccarino L, Sarzi-Puttini P, Atzeni F, Turriel M, Petri M (2005) Cardiac involvement in systemic lupus erythematosus. Lupus 14(9):683–686CrossRefPubMed Doria A, Iaccarino L, Sarzi-Puttini P, Atzeni F, Turriel M, Petri M (2005) Cardiac involvement in systemic lupus erythematosus. Lupus 14(9):683–686CrossRefPubMed
5.
go back to reference Nossent J, Cikes N, Kiss E, Marchesoni A, Nassonova V, Mosca M, Olesinska M, Pokorny G, Rozman B, Schneider M, Vlachoyiannopoulos PG, Swaak A (2007) Current causes of death in systemic lupus erythematosus in Europe, 2000–2004: relation to disease activity and damage accrual. Lupus 16(5):309–317CrossRefPubMed Nossent J, Cikes N, Kiss E, Marchesoni A, Nassonova V, Mosca M, Olesinska M, Pokorny G, Rozman B, Schneider M, Vlachoyiannopoulos PG, Swaak A (2007) Current causes of death in systemic lupus erythematosus in Europe, 2000–2004: relation to disease activity and damage accrual. Lupus 16(5):309–317CrossRefPubMed
7.
go back to reference Paran D, Fireman E, Elkayam O (2004) Pulmonary disease in systemic lupus erythematosus and the antiphospholipid syndrome. Autoimmun Rev 3(1):70–75CrossRefPubMed Paran D, Fireman E, Elkayam O (2004) Pulmonary disease in systemic lupus erythematosus and the antiphospholipid syndrome. Autoimmun Rev 3(1):70–75CrossRefPubMed
8.
go back to reference Djokovic A, Stojanovich L, Kontic M, Stanisavljevic N, Radovanovic S, Marisavljevic D (2014) Association between cardiac manifestations and antiphospholipid antibody type and level in a cohort of Serbian patients with primary and secondary antiphospholipid syndrome. The Israel Medical Association journal : IMAJ 16(3):162–167PubMed Djokovic A, Stojanovich L, Kontic M, Stanisavljevic N, Radovanovic S, Marisavljevic D (2014) Association between cardiac manifestations and antiphospholipid antibody type and level in a cohort of Serbian patients with primary and secondary antiphospholipid syndrome. The Israel Medical Association journal : IMAJ 16(3):162–167PubMed
9.
go back to reference Nihoyannopoulos P, Gomez PM, Joshi J, Loizou S, Walport MJ, Oakley CM (1990) Cardiac abnormalities in systemic lupus erythematosus. Association with raised anticardiolipin antibodies. Circulation 82(2):369–375CrossRefPubMed Nihoyannopoulos P, Gomez PM, Joshi J, Loizou S, Walport MJ, Oakley CM (1990) Cardiac abnormalities in systemic lupus erythematosus. Association with raised anticardiolipin antibodies. Circulation 82(2):369–375CrossRefPubMed
10.
go back to reference Elliott JR, Manzi S (2009) Cardiovascular risk assessment and treatment in systemic lupus erythematosus. Best Pract Res Clin Rheumatol 23(4):481–494CrossRefPubMed Elliott JR, Manzi S (2009) Cardiovascular risk assessment and treatment in systemic lupus erythematosus. Best Pract Res Clin Rheumatol 23(4):481–494CrossRefPubMed
11.
go back to reference Petri M, Magder L (2004) Classification criteria for systemic lupus erythematosus: a review. Lupus 13(11):829–837CrossRefPubMed Petri M, Magder L (2004) Classification criteria for systemic lupus erythematosus: a review. Lupus 13(11):829–837CrossRefPubMed
12.
go back to reference Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, Urowitz M, Fortin PR, Petri M, Barr S, Gordon C, Bae SC, Isenberg D, Zoma A, Aranow C, Dooley MA, Nived O, Sturfelt G, Steinsson K, Alarcon G, Senecal JL, Zummer M, Hanly J, Ensworth S, Pope J, Edworthy S, Rahman A, Sibley J, El-Gabalawy H, McCarthy T, St Pierre Y, Clarke A, Ramsey-Goldman R (2006) Mortality in systemic lupus erythematosus. Arthritis Rheum 54(8):2550–2557. doi:10.1002/art.21955 CrossRefPubMed Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, Urowitz M, Fortin PR, Petri M, Barr S, Gordon C, Bae SC, Isenberg D, Zoma A, Aranow C, Dooley MA, Nived O, Sturfelt G, Steinsson K, Alarcon G, Senecal JL, Zummer M, Hanly J, Ensworth S, Pope J, Edworthy S, Rahman A, Sibley J, El-Gabalawy H, McCarthy T, St Pierre Y, Clarke A, Ramsey-Goldman R (2006) Mortality in systemic lupus erythematosus. Arthritis Rheum 54(8):2550–2557. doi:10.​1002/​art.​21955 CrossRefPubMed
13.
go back to reference Lin CC, Ding HJ, Chen YW, Wang JJ, Ho ST, Kao A (2003) Usefulness of technetium-99 m sestamibi myocardial perfusion SPECT in detection of cardiovascular involvement in patients with systemic lupus erythematosus or systemic sclerosis. Int J Cardiol 92(2–3):157–161CrossRefPubMed Lin CC, Ding HJ, Chen YW, Wang JJ, Ho ST, Kao A (2003) Usefulness of technetium-99 m sestamibi myocardial perfusion SPECT in detection of cardiovascular involvement in patients with systemic lupus erythematosus or systemic sclerosis. Int J Cardiol 92(2–3):157–161CrossRefPubMed
14.
go back to reference Lin JJ, Hsu HB, Sun SS, Wang JJ, Ho ST, Kao CH (2003) Single photon emission computed tomography of technetium-99m tetrofosmin myocardial perfusion imaging in patients with systemic lupus erythematosus—a preliminary report. Jpn Heart J 44(1):83–89CrossRefPubMed Lin JJ, Hsu HB, Sun SS, Wang JJ, Ho ST, Kao CH (2003) Single photon emission computed tomography of technetium-99m tetrofosmin myocardial perfusion imaging in patients with systemic lupus erythematosus—a preliminary report. Jpn Heart J 44(1):83–89CrossRefPubMed
15.
go back to reference de Godoy MF, de Oliveira CM, Fabri VA, de Abreu LC, Valenti VE, Pires AC, Raimundo RD, Figueiredo JL, Bertazzi GR (2013) Long-term cardiac changes in patients with systemic lupus erythematosus. BMC research notes 6:171. doi:10.1186/1756-0500-6-171 de Godoy MF, de Oliveira CM, Fabri VA, de Abreu LC, Valenti VE, Pires AC, Raimundo RD, Figueiredo JL, Bertazzi GR (2013) Long-term cardiac changes in patients with systemic lupus erythematosus. BMC research notes 6:171. doi:10.​1186/​1756-0500-6-171
16.
go back to reference Roman MJ, Salmon JE, Sobel R, Lockshin MD, Sammaritano L, Schwartz JE, Devereux RB (2001) Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Am J Cardiol 87(5):663–666 A611CrossRefPubMed Roman MJ, Salmon JE, Sobel R, Lockshin MD, Sammaritano L, Schwartz JE, Devereux RB (2001) Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Am J Cardiol 87(5):663–666 A611CrossRefPubMed
17.
go back to reference Ong ML, Veerapen K, Chambers JB, Lim MN, Manivasagar M, Wang F (1992) Cardiac abnormalities in systemic lupus erythematosus: prevalence and relationship to disease activity. Int J Cardiol 34(1):69–74CrossRefPubMed Ong ML, Veerapen K, Chambers JB, Lim MN, Manivasagar M, Wang F (1992) Cardiac abnormalities in systemic lupus erythematosus: prevalence and relationship to disease activity. Int J Cardiol 34(1):69–74CrossRefPubMed
18.
go back to reference Leung WH, Wong KL, Lau CP, Wong CK, Cheng CH (1990) Cardiac abnormalities in systemic lupus erythematosus: a prospective M-mode, cross-sectional and Doppler echocardiographic study. Int J Cardiol 27(3):367–375CrossRefPubMed Leung WH, Wong KL, Lau CP, Wong CK, Cheng CH (1990) Cardiac abnormalities in systemic lupus erythematosus: a prospective M-mode, cross-sectional and Doppler echocardiographic study. Int J Cardiol 27(3):367–375CrossRefPubMed
19.
go back to reference Hameed S, Malik LM, Shafi S, Azeem S, Shahzad A (2007) Echocardiographic evaluation of patients with systemic lupus erythematosus. Pakistan Journal of Medical Sciences 23(4):497–500 Hameed S, Malik LM, Shafi S, Azeem S, Shahzad A (2007) Echocardiographic evaluation of patients with systemic lupus erythematosus. Pakistan Journal of Medical Sciences 23(4):497–500
20.
go back to reference Perez-Villa F, Font J, Azqueta M, Espinosa G, Pare C, Cervera R, Reverter JC, Ingelmo M, Sanz G (2005) Severe valvular regurgitation and antiphospholipid antibodies in systemic lupus erythematosus: a prospective, long-term, followup study. Arthritis Rheum 53(3):460–467. doi:10.1002/art.21162 CrossRefPubMed Perez-Villa F, Font J, Azqueta M, Espinosa G, Pare C, Cervera R, Reverter JC, Ingelmo M, Sanz G (2005) Severe valvular regurgitation and antiphospholipid antibodies in systemic lupus erythematosus: a prospective, long-term, followup study. Arthritis Rheum 53(3):460–467. doi:10.​1002/​art.​21162 CrossRefPubMed
21.
go back to reference Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot P, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of thrombosis and haemostasis : JTH 4(2):295–306. doi:10.1111/j.1538-7836.2006.01753 CrossRefPubMed Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot P, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of thrombosis and haemostasis : JTH 4(2):295–306. doi:10.​1111/​j.​1538-7836.​2006.​01753 CrossRefPubMed
22.
go back to reference Amigo MC, Garcia-Torres R (2000) Morphology of vascular, renal, and heart lesions in the antiphospholipid syndrome: relationship to pathogenesis. Curr Rheumatol Rep 2(3):262–270CrossRefPubMed Amigo MC, Garcia-Torres R (2000) Morphology of vascular, renal, and heart lesions in the antiphospholipid syndrome: relationship to pathogenesis. Curr Rheumatol Rep 2(3):262–270CrossRefPubMed
Metadata
Title
Echocardiographic findings in asymptomatic systemic lupus erythematosus patients
Authors
Abdel GaffarA. Mohammed
Abdulaziz A. Alghamdi
Mohammad A. ALjahlan
Ibrahim A. AL-Homood
Publication date
01-03-2017
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 3/2017
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-016-3486-4

Other articles of this Issue 3/2017

Clinical Rheumatology 3/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine